On October 2, 2026, California's emergency regulations implementing AB 1415 took effect — immediately, with no grace period. The rules extend transaction review by the Office of Health Care Affordability (OHCA) to private equity groups, hedge funds, management services organizations (MSOs), and a set of newly created entities, and they move the control trigger for PE and hedge fund investors from 5% to 10% of a target's equity or debt interests. If you are signing or negotiating a healthcare transaction that touches California after October 2, the closing schedule you drafted last month should be updated.

This piece is a working plan for fixing that. It is written for sponsors, MSO operators, and executives who have a live deal or a term sheet in hand.

What changed, in plain terms

Three things matter commercially.

1. More parties have to file. The regulations add classes of "noticing entities" beyond the health care entities that filed under the original statute. A private equity group or hedge fund that is a party to a covered transaction with an MSO or health care entity must now file. MSOs must file if they meet certain ownership, staffing, or affiliation criteria — including sharing directors, officers, or investors with a health care entity. Newly formed deal entities must file. Entities that own, operate, or control a provider must file, even where the provider is not yet operating or holds a suspended license.

2. The notice window is 90 days before closing and review is mandatory. Notice must be submitted at least 90 days before the transaction closes, and the transaction may not close until OHCA completes its review. Approval is a Cost and Market Impact Review (“CMIR”) waiver or a completed in-depth CMIR. If OHCA decides to initiate a CMIR, it has 90 days to complete it (with extensions possible). That is a regulatory hold. It does not matter that your financing expires in 120 days or that your target's fiscal year closes on January 31. You must file the notice and OHCA must issue either a waiver or a final report.

3. The disclosure burden is portfolio-wide. Filers must produce organizational charts tracing ownership up to the ultimate parent, identify all persons with 5% or more ownership, and disclose every health care entity and MSO the sponsor directly or indirectly owns, controls, or finances — not only California entities. The filer must also produce internal documents presented to its governing body about the transaction, quality-of-care ratings, anticipated cost savings, and, for PE and hedge funds, post-closing leverage plans. For a sponsor with a multi-state healthcare portfolio, this is a data collection project measured in weeks, not days.

The dollar thresholds are unchanged: $25 million in annual revenue or California assets, with a secondary $10 million trigger for certain counterparties. The 10% control trigger replaces the 5% threshold from the May draft — a concession to commenters, but not a reason to skip the analysis.

What to do with a live deal

1. Build the notice into the timeline before you sign. The OHCA notice and clearance is a closing condition. The purchase agreement should require seller cooperation with the filing, allocate responsibility for preparing the disclosure package, and set the filing deadline at least 90 days before the scheduled closing date — with a buffer. A 90-day statutory review period plus agency questions does not fit inside a 100-day financing commitment.

2. Scope the disclosure workstream at the term sheet stage. The ownership chart to the ultimate parent, the 5% holder list, and the portfolio-wide healthcare holdings inventory cannot be assembled in the two weeks before filing. Assign it when you assign diligence. If the sponsor's internal records are weak, fix that gap before you sign, not after.

3. Price the delay into the deal. Closing delay is a California regulatory feature for covered transactions. That affects holdback mechanics, financing expiration dates, purchase price adjustments tied to a projected closing date, and material adverse effect analysis. If the target has revenue concentration in California, treat the OHCA window as a known risk with a known cost, and negotiate who bears it.

4. Check the debt side. The control trigger extends to debt interests. A lender taking 10% or more of a target's debt in a restructuring or a debt-for-equity scenario can trigger the filing obligation. Credit agreements and workout documents should address whether the borrower or the sponsor controls the OHCA filing and who bears the delay cost.

5. Paper the representation. Buyers and sellers should rep that no OHCA notice obligation exists or that the notice has been filed or will be filed and the review period has run. Buyers should require it. If both sides are wrong, the closing cannot lawfully occur — and the remedy for that mistake should be allocated in the agreement, not litigated after it.

What this is not

OHCA alone cannot block a deal from going through: the emergency regulations are a process rule, not a substantive prohibition. OHCA reviews transactions for cost, quality, and market effects; it does not approve or reject them. That distinction matters in communications with a deal committee: this is a compliance gate with a clock, not a second antitrust review.

That is not to say that a negative CMIR finding could not be used to trigger additional regulatory requirements or limit how a private equity group, hedge fund, or MSO deal is structured or if it is permitted to close. OHCA specifically says that its reviews may lead to coordination with other state agencies to address consolidation “as appropriate.” Most transactions are unlikely to undergo a CMIR – only two have since the predecessor to AB 1415 requiring pre-transaction submission was enacted.

The new risks from AB 1415 and these emergency regulations are delays in closing, AG enforcement actions over premature closing, and voiding of certain deals if ultimately found to violate the law.

The emergency regulations also remain subject to revision. The California Office of Administrative Law approved them under an emergency pathway, and permanent rulemaking will follow. Track the permanent regulations before your next deal closes; the 10% trigger and the disclosure scope are the two items most likely to move.

The practical takeaway

California has joined the states, including Illinois, Massachusetts, and New York, treating healthcare deal review as a pre-closing exercise rather than a post-closing disclosure. Sponsors that build the OHCA notice into the deal calendar, assign portfolio-wide disclosure collection early, and allocate the delay risk in the purchase agreement will close on schedule. Sponsors that treat the October 2 rules as a footnote will miss closings, or worse, close without authority. The fix is procedural, and it is knowable now. Use it.

About the Author

Kristie M. Blase advises health care clients on transactions, regulatory matters, and the governance and contracting issues that shape growth. She represents sponsors, operators, providers, and health technology companies in M&A, financing, and regulatory-risk matters nationwide. Kristie is based in New York and Texas.